Introduction and Business Overview
Merck & Co. (NYSE: MRK) is a global pharmaceutical leader with a diversified portfolio of human medicines, vaccines, and animal health products ([1]) ([1]). The company’s pharmaceutical segment drives the majority of revenue, with flagship products like the cancer immunotherapy Keytruda and HPV vaccine Gardasil at the forefront ([1]) ([1]). In 2023, Keytruda alone contributed over $25 billion in sales (about 40% of Merck’s $60 billion revenue) ([1]). This heavy reliance on Keytruda underscores the urgency for new growth drivers as its U.S. exclusivity faces a late-decade expiration (expected in 2028) ([2]) ([2]). Merck has responded by investing aggressively in its pipeline and strategic acquisitions – notably the $11.5 billion Acceleron buyout that delivered Winrevair (sotatercept) ([3]). Winrevair is a first-in-class therapy for pulmonary arterial hypertension (PAH) that Merck believes could help fill the post-Keytruda gap and even “revolutionize” treatment for certain heart conditions. This report provides a deep dive into Merck’s financial health and valuation, while exploring how Winrevair and other pipeline assets might shape its future.
Key Products and the Rise of Winrevair
Keytruda (anti-PD-1 immunotherapy) remains Merck’s top product, with third-quarter 2025 sales of $8.1 billion – now representing nearly half of the company’s revenue ([4]). Gardasil/Gardasil 9 (HPV vaccines) is another pillar, although Q3 2025 sales dipped to $1.75 billion amid weaker demand in China ([4]). Merck’s portfolio also includes diabetes drugs (Januvia/Janumet), vaccines (ProQuad, RotaTeq, Vaxneuvance), and an Animal Health division contributing roughly $5–6 billion annually ([1]) ([1]). However, many of Merck’s legacy drugs face patent expirations or competitive pressures. For example, Januvia’s U.S. market exclusivity ends in 2026 ([2]) and Gardasil 9’s core patents expire by 2028–2030 in major markets ([2]). Crucially, Keytruda is widely expected to encounter biosimilar competition by 2028, aligning with U.S. drug price negotiation timelines ([2]). This looming “patent cliff” has sharpened investor focus on Merck’s pipeline of new therapies.
Winrevair has emerged as one of Merck’s most promising new drugs. Acquired via Acceleron, Winrevair (generic name sotatercept) is an activin signaling inhibitor and the first FDA-approved therapy of its kind ([5]). It won U.S. approval in March 2024 for pulmonary arterial hypertension (PAH) – a rare, progressive cardiovascular condition – to improve exercise capacity and slow disease progression ([2]) ([5]). Notably, Winrevair’s pivotal trial showed it “significantly reduced the risk of death” and delayed clinical worsening, including need for lung transplant ([5]). An independent committee even recommended halting a Phase 3 PAH study early due to clear efficacy ([5]). This drug, priced around $238,000 per year in the U.S., generated $149 million in Q3 2024 after its launch ([5]). While the initial rollout was somewhat slow – likely due to physicians’ cautiousness over bleeding side effects – real-world data suggest bleeding risk may be lower than expected ([6]) ([6]). As confidence grows, adoption is accelerating: in Q3 2025, Winrevair sales jumped to $360 million for the quarter (nearly 2.5× the year-ago level), totaling $976 million in the first nine months of 2025 ([3]).
Beyond PAH, Winrevair is now breaking new ground in heart failure. A Phase 2 trial (CADENCE) in patients with combined pre- and post-capillary pulmonary hypertension due to heart failure with preserved ejection fraction (HFpEF) just met its primary endpoint ([3]). Merck reported that Winrevair improved blood flow through the lungs to the heart in this tough-to-treat subset of HFpEF, yielding a statistically significant reduction in pulmonary vascular resistance (a key hemodynamic measure) ([3]) ([3]). There are currently no approved treatments for this form of pulmonary hypertension caused by left-heart disease ([3]), so Winrevair’s success could be transformative. Merck plans to advance Winrevair into Phase 3 for HFpEF with CpcPH (combined pre-/post-capillary PH) ([3]) ([3]). Analysts are enthusiastic – Citi termed the data a “new population unlocked” and projects Winrevair could reach $6.2 billion in sales by 2030 if it secures expanded indications ([3]) ([3]). Even Merck’s in-house forecasts have envisioned at least $3 billion in peak sales for Winrevair in PAH alone ([6]). In short, Winrevair appears poised to graduate from a niche rare-disease drug into a multi-billion-dollar franchise, potentially revolutionizing treatment for both advanced PAH and a segment of heart failure previously lacking options.
Dividend Policy and Shareholder Returns
Merck is a long-standing dividend payer with a track record of steady increases. The quarterly dividend was raised to $0.81 per share for the first quarter of 2025 (up from $0.77), marking the 12th consecutive annual increase ([2]) ([2]). Over 2020–2024, Merck’s dividend per share climbed from $2.48 to $3.12, a roughly 6% compounded annual growth rate ([7]). The trailing 12-month payout is about $3.24 per share, equating to a dividend yield in the mid-3% range at recent prices ([7]). (Notably, during a market dip in early 2025, Merck’s yield briefly topped 4% when the stock traded below $80 ([8]).) This above-market yield reflects Merck’s mature cash-generating profile and some investor caution around its post-2028 growth, but the dividend itself appears well-supported. In 2024, Merck paid out $7.8 billion in dividends, which was about 36% of that year’s $21.5 billion in operating cash flow ([2]) ([2]). Even including share buybacks, total capital returned to shareholders ($9.1 billion in 2024) was under half of free cash flow ([2]). This implies a comfortable coverage ratio, with free cash flow exceeding dividend outlays by roughly 2×. The payout ratio based on adjusted earnings remains moderate as well (~46% for 2024) ([7]) ([7]). Merck’s management has reaffirmed commitment to the dividend, prioritizing it alongside value-enhancing acquisitions and R&D investment ([2]). Investors can likely expect continued modest dividend growth, supported by Merck’s robust cash flows from its entrenched drug franchises.
Leverage, Debt Maturities, and Coverage
Merck maintains a solid balance sheet with manageable leverage. As of year-end 2024, total debt was $37.1 billion (including $2.65 billion due within one year) ([2]). The company held over $13.7 billion in cash and short-term investments, bringing net debt down to roughly $23 billion ([2]) ([2]). This net debt is modest relative to Merck’s earnings power – about 1.0× 2024 EBITDA on an adjusted basis, by our estimates. Credit agencies rate Merck’s debt in the single-A range (indicating low credit risk), and Merck retains ample liquidity via a $6 billion undrawn credit facility maturing 2028 ([2]). Near-term debt maturities are not onerous: the next significant bond maturity is in 2026 (1.875% notes) and other large issuances are long-dated into the 2030s and 2040s ([1]). In addition, Merck can tap commercial paper markets for short-term funding at low cost; the credit line serves as backup for that program ([2]).
Interest expense was $1.27 billion in 2024, up slightly from $1.15 billion in 2023 as debt increased to fund acquisitions ([2]) ([2]). Even so, interest is well-covered by earnings and cash flow. In 2024, operating cash flow was $21.5 billion – roughly 17× the annual interest burden, indicating very strong interest coverage ([2]) ([2]). On a earnings basis, 2024 GAAP net income rebounded to about $17 billion (after an unusual dip to $365 million in 2023 due to one-time R&D write-offs) ([2]) ([2]). The return to robust profitability in 2024 drove Merck’s debt-to-equity ratio down to ~0.8:1 (debt of $37 billion vs. $46 billion in total equity) ([2]) ([2]). Overall, the company’s balance sheet strength and cash generation provide ample cushion for debt servicing, continued dividends, and strategic investments. Merck has prudently kept leverage in check even while executing multi-billion acquisitions like Acceleron and Prometheus. This conservative financial profile should help Merck navigate any volatility as Keytruda’s patent expiry approaches.
Valuation and Peer Comparison
Merck’s shares trade at a valuation reflecting its stable current business and uncertainties about future growth. At a recent price in the low-$90s, MRK stock carries a forward price-to-earnings (P/E) ratio around 11×–12× based on 2025 adjusted EPS guidance (~$8.95) ([4]). On a trailing basis, Merck’s P/E is distorted by 2023’s GAAP earnings anomaly, but using 2024’s normalized EPS (~$6.74) the multiple is roughly 13–14× ([7]). This is a modest discount to the broader market and roughly in line with other big pharma peers facing patent cliffs. For instance, Bristol Myers Squibb and Pfizer trade at single-digit forward P/Es (reflecting their own looming patent/exclusivity losses and, in Pfizer’s case, a COVID comedown), while Johnson & Johnson and AbbVie are in the low-teens. By contrast, high-growth pharma like Eli Lilly (buoyed by obesity drug prospects) commands a much richer ~30–40× multiple. Merck’s dividend yield ~3.5% also stacks up as fairly attractive – higher than J&J (~3%) and Lilly (~1%), though a bit below Pfizer’s recent 5%+ yield ([8]). This yield support indicates investors view Merck as a more mature, income-generating investment at present. Notably, Merck’s free cash flow yield (FCF/market cap) is around 7–8%, reinforcing the sense of a value proposition if future earnings can be sustained or grown. Its EV/EBITDA in the high-single-digits likewise suggests the market has tempered expectations. In sum, Merck’s valuation appears reasonable and perhaps even undemanding given its pipeline catalysts – but the market is clearly taking a “show me” stance on whether new drugs like Winrevair can offset the eventual Keytruda decline.
Risks and Red Flags
Despite its strengths, Merck faces several risks and red flags that investors should monitor:
– Patent Expirations & Concentration: The biggest risk is the upcoming patent cliff for Keytruda. With U.S. loss of exclusivity in 2028 ([2]) ([2]), Merck could see its largest source of profit erode quickly if biosimilar competition emerges. Keytruda contributed ~47% of Q3 2025 sales ([4]), an extraordinary concentration. Gardasil 9 (over 13% of sales) also faces patent expiry by 2028–2030 ([2]). Failure to replace these revenues would severely impact Merck’s earnings in the late-2020s.
– Pipeline Reliance & Execution: While Merck’s pipeline is promising (Winrevair, an oral PCSK9 inhibitor, the Prometheus immunology drug, etc.), it carries development and commercial risk. Not all pipeline candidates will succeed. For example, Merck paid ~$10.8 billion for Prometheus Biosciences in 2023 to acquire a Phase 2 ulcerative colitis drug; if that therapy fails in Phase 3 or faces safety issues, the investment may not pay off. Merck’s heavy R&D spending and acquisition charges (which caused the 2023 earnings dip) highlight the risk of pipeline bets not yielding timely payback ([1]) ([1]).
Start collecting royalty checks before the first national payout.
Step 1
Learn the exact royalty play paying monthly checks
Step 2
Start with as little as $50 — get paid next month
Step 3
Position yourself before Wall Street moves in
– Competitive and Market Dynamics: In Merck’s core oncology business, competitors are developing next-generation immunotherapies that could challenge Keytruda’s dominance. In cardiovascular and pulmonary fields, Winrevair’s novel mechanism (activin pathway) is also being pursued by others – e.g. a rival PAH drug by Keros Therapeutics had similar targets but encountered safety setbacks (pericardial effusion), reflecting potential class effects ([6]). New competition or unforeseen side effects could limit Winrevair’s uptake. Additionally, Merck’s dependence on China for Gardasil growth proved a double-edged sword; economic or regulatory changes there have already dampened vaccine demand ([4]), and domestic Chinese vaccine developers could emerge over time.
– Drug Pricing and Regulatory Headwinds: The U.S. healthcare landscape is shifting with reforms that may pressure pricing. Under the Inflation Reduction Act, Medicare will begin negotiating prices on top-selling drugs. Merck expects Keytruda will be subject to Medicare price setting as early as 2028 ([2]) if it’s still on market without competition. Government pricing power (and international reference pricing trends) could squeeze Merck’s margins on mature drugs. Moreover, any tightening of FDA safety standards or surprise clinical trial issues (e.g., unforeseen adverse events) pose regulatory risk for pipeline candidates.
– Litigation and Legal Uncertainties: Major pharmaceutical companies routinely face litigation (patent challenges, product liability suits, etc.). While Merck’s $4.85 billion Vioxx settlement is well in the past, the company recently paid over $570 million in 2023 to settle an antitrust case related to cholesterol drugs ([2]). Legal liabilities of this scale, though infrequent, can impact cash flow. Ongoing patent litigation – for instance, patent defense for Keytruda formulations or devices – could also influence when generic competition begins in different regions.
Overall, Merck’s risks underscore the execution required in the next few years. The company must successfully launch new products and potentially consider additional deals to diversify its revenue – all while managing the tail end of Keytruda’s exclusivity.
Open Questions and Outlook
Looking ahead, several open questions will determine Merck’s trajectory and whether Winrevair truly heralds a new era in cardiovascular treatment:
– Can Winrevair expand beyond PAH into the broader heart failure market? The upcoming Phase 3 program in HFpEF with pulmonary hypertension will be critical. If Winrevair reproduces its Phase 2 success, it could become the first approved therapy for this HF subset ([3]). That would not only save lives but also significantly enlarge Winrevair’s addressable market. However, failure or safety issues in Phase 3 would temper enthusiasm for Winrevair’s “revolutionary” potential.
– How quickly will Winrevair’s sales ramp and peak? Current consensus has peak sales ranging from Merck’s $3 billion estimate (for PAH) to bullish analysts seeing $5–6 billion with new indications ([3]) ([6]). The actual trajectory will depend on physician adoption, real-world outcomes, and competition. Early uptake was somewhat cautious due to bleeding risk concerns ([6]), but real-world data is easing those fears. Investors will be watching if Winrevair can sustain its strong 2025 momentum into 2026 and beyond.
– Will Merck’s other pipeline candidates deliver? Beyond Winrevair, Merck’s oral PCSK9 inhibitor (enlicitide) showed positive Phase 3 results in lowering LDL cholesterol ([9]) ([9]). If approved, an oral PCSK9 could be a game-changer in cholesterol management, tapping a huge market dominated by injectables. Similarly, the immunology drug from Prometheus (targeting TL1A in autoimmune disease) is a high-profile bet. Success from these programs could materially boost late-decade revenue – but setbacks would raise pressure on management to find alternatives.
– How will Merck navigate the Keytruda cliff? Even with promising new drugs, replacing ~$30 billion of prospective Keytruda sales (projected for 2024–2025) is an enormous challenge ([2]) ([2]). Merck is likely to lean on business development in oncology (or other high-growth areas) to supplement internal R&D. An open question is whether Merck will pursue larger acquisitions to bolster its portfolio (as Pfizer and Amgen have done), or continue targeted bolt-ons. The company’s willingness to deploy its healthy balance sheet for the right deal could be tested as 2028 draws closer.
– What will be the impact of healthcare policy changes? U.S. drug price negotiations, potential expansion of Medicare coverage changes, and international pricing pressures all create uncertainty in long-term forecasts. For example, if Keytruda’s price is forced down significantly in its final years of exclusivity, it could accelerate the revenue decline pre-biosimilars ([2]). It remains to be seen how Merck will adapt – through portfolio focus, cost cuts, or volume strategies – in an era of increasing price scrutiny.
In summary, Merck’s investment thesis in the mid-2020s hinges on successful innovation to offset maturity in its legacy blockbusters. Winrevair’s early successes in PAH – and potentially in heart failure – exemplify the kind of innovation Merck needs to sustain growth. The company’s fundamentals (strong cash flows, manageable debt, and a shareholder-friendly dividend) provide a solid foundation as it confronts these strategic questions. If Merck can execute on its pipeline and navigate the patent cliffs, the current valuation could prove attractive. However, investors will be closely tracking these open questions for signs of whether Merck’s “next act” – led by therapies like Winrevair – can truly revolutionize treatment paradigms and revitalize the company’s growth.
Sources: Merck 10-K and financial filings ([2]) ([2]); Merck press releases and investor materials ([9]) ([3]); Reuters and FiercePharma reports ([5]) ([3]); analyst commentary via FiercePharma ([3]) ([3]); Marketscreener and Nasdaq data for share price and dividends ([7]) ([8]).
Sources
- https://sec.gov/Archives/edgar/data/310158/000162828024006850/mrk-20231231.htm
- https://sec.gov/Archives/edgar/data/310158/000162828025007732/mrk-20241231.htm
- https://fiercepharma.com/pharma/merck-advances-winrevair-subset-heart-failure-patients
- https://reuters.com/business/healthcare-pharmaceuticals/merck-posts-higher-third-quarter-sales-keytruda-growth-offsets-drop-gardasil-2025-10-30/
- https://reuters.com/business/healthcare-pharmaceuticals/mercks-therapy-rare-lung-condition-shown-help-reduce-risk-death-study-2024-11-25/
- https://fiercepharma.com/pharma/mercks-winrevair-poised-strong-uptake-2025-leerink
- https://ae.marketscreener.com/quote/stock/MERCK-CO-INC-13611/valuation-dividend/
- https://nasdaq.com/articles/merck-mrk-shares-cross-4-yield-mark
- https://merck.com/news/merck-to-present-new-data-from-its-innovative-cardio-pulmonary-pipeline-and-portfolio-at-aha-scientific-sessions-2025/
For informational purposes only; not investment advice.
